

Western Region Drugs Task Force Company Limited By Guarantee
Annual Report and Financial Statements
for the financial year ended 31 December 2021

Western Region Drugs Task Force Company Limited By Guarantee

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 6
Directors' Responsibilities Statement	7
Independent Auditor's Report	8 - 9
Appendix to the Independent Auditor's Report	10
Income and Expenditure Account	11
Balance Sheet	12
Reconciliation of Members' Funds	13
Cash Flow Statement	14
Notes to the Financial Statements	15 - 24
Supplementary Information on Trading Statement	26 - 27

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS AND OTHER INFORMATION

Directors	Richard O'Donovan (Resigned 1 March 2022) Joseph O'Neill Joseph McDonagh Noel Cronin (Appointed 1 March 2021)
Company Secretary	Joseph O'Neill
Company Number	460340
Charity Number	CHY18126
Registered Office	Unit 6 Galway Technology Park Parkmore Galway
Business Address	Unit 6 Galway Technology Park Parkmore Galway
Auditors	DFS & Co Audit Services Limited Chartered Accountants & Statutory Audit Firm 2nd Floor Innovation House Ballybrit Business Park Ballybrit Galway
Bankers	Bank of Ireland Mainguard Street Galway
Solicitors	Sheehan & Co Solicitors Augustine Court St Augustine Street Galway

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS' REPORT

for the financial year ended 31 December 2021

The directors present their report and the audited financial statements for the financial year ended 31 December 2021.

Principal Activity and Review of the Business

The organisation is a charitable company limited by guarantee, incorporated under the Companies Act 2014 on 24th July 2008. The company does not have a share capital and consequently the liability of member is limited, subject to an undertaking by each member to contribute to the net assets and liabilities of the company on winding up such amounts as may be required not exceeding one Euro (€1). The company was established under a Memorandum of Association which established the objects and powers of the charitable status under Section 207 and 2018 of the Taxes Consolidation Act 1977, Charity No CHY 18126.

The principal activity of the charity is to develop and implement an integrated community, voluntary and statutory strategy to combat substance abuse in Galway, Mayo & Roscommon.

The company is involved in proposing a range of solutions and service interventions based on the pillars of the National Drugs Strategy and ensures that responses are monitored and evaluated according to best practice and value for money principles. In addition, it is responsible for interagency co-ordination.

The charity's main activities are as follows:

- Central funding is received for the purpose of an operational budget to run the charity's operation of which the main cost is rent for the premises and office & printing costs. In addition, the funding is to be used for the purpose of distributing funds to specific projects including a regional anti-drugs advertising campaign, family support programmes, design and print of manuals to further the aims of the charity and other projects being run by the charity.
- In addition, the company launched a plant youth project based on an Icelandic model. The project involved visiting secondary schools throughout the region, giving talks & carrying out surveys. The funding for this project was obtained from Tusla, the HSE and County Councils in the region.
- During 2021, the company entered into a Bursary project whereby €10,000 and a further €7,555 which was carried forward from 2020 was spent on granting bursaries to individuals who required rehabilitation.
- In addition, the HSE provided funding of €106,326 during the year to ensure that a Family Support Worker was in place the Ballinrobe Family Resource Centre & the Arduan, Roscam & Doughiska Family Resource Centre.

Principal Risks & Uncertainties

The directors have identified that the key risks and uncertainties the organisation faces relate to:

- The risks associated with the Covid 19 pandemic to the safety of our clients & volunteers and its impact on our ability to continue the delivery of the essential services that we provide.
- The increase in demand for our services due to the increase in substance abuse during the Covid 19 pandemic.
- The reliance of the organisation on government and state agencies for funding and the impact of government cut backs on the ability to provide required services.
- The risk of inadequate resources to support a fit for purpose organisational structure to meet increasing service needs, compliance requirements and associated IT infrastructure, in accordance with company, governance, health & safety, GDPR and other legislation.

The company mitigates these risks as follows: -

- Operating to the highest standards of infection control across all services as per our Covid 19 protocols and according to ongoing government advice.
- Continuing to develop strong advocacy function to support clients to access our services.
- Continuing to lobby government & state funders to recognise the importance of increased funding in line with increasing needs and to support a fit for purpose support structure enabling best practice service delivery and standards.
- Continually monitoring the level of activity and preparing and monitoring its budgets, target and projections.
- Closely monitoring emerging changes to regulations and legislation on an on-going basis.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with governance standards, health & safety of clients, volunteers & visitors and all other legislative requirements.

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS' REPORT

for the financial year ended 31 December 2021

Financial Results

The surplus/(deficit) for the financial year after providing for depreciation amounted to €3,700 (2020 - €(10,825)).

At the end of the financial year, the company has assets of €28,188 (2020 - €70,977) and liabilities of €6,355 (2020 - €52,844). The net assets of the company have increased by €3,700.

Reserves Strategy

The Board has set a reserves policy which requires reserves to be maintained at a level which would cover Western Region Drugs Taskforce's operating costs for a month. This would enable current operating activities to continue in the short term should there be a significant drop in funding. At least one months operating costs should be maintained in a cash or cash equivalent reserve.

Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Richard O'Donovan (Resigned 1 March 2022)

Joseph O'Neill

Joseph McDonagh

Noel Cronin (Appointed 1 March 2021)

The secretary who served throughout the financial year was Joseph O'Neill.

During the year, Western Region Drugs Task Force's Board of Management held six board meetings. Joseph O'Neill attended all six of these meetings, while Joseph McDonagh attended four of the meetings. Richard O'Donovan was unable attend any of the meetings during the year.

Future Developments

The company has no plans to alter its activities or operations for the foreseeable future.

Post Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Political Contributions

The company did not make any disclosable political donations in the current financial year.

Auditors

The auditors, DFS & Co Audit Services Limited, (Chartered Accountants & Statutory Audit Firm) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

Western Region Drugs Task Force Company Limited By Guarantee


DIRECTORS' REPORT


for the financial year ended 31 December 2021

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at Unit 6 Galway Technology Park, Parkmore, Galway.

Signed on behalf of the board



Joseph O'Neill
Director

Joseph McDonagh
Director

29 March 2022

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2021

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:


- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Joseph O'Neill
Director



Joseph McDonagh
Director

29 March 2022

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Western Region Drugs Task Force Company Limited By Guarantee ('the company') for the financial year ended 31 December 2021 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2021 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 7, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.


Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 10, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Brian Feeney
for and on behalf of
DFS & CO AUDIT SERVICES LIMITED
Chartered Accountants & Statutory Audit Firm
2nd Floor
Innovation House
Ballybrit Business Park
Ballybrit
Galway

29 March 2022

Western Region Drugs Task Force Company Limited By Guarantee

APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Western Region Drugs Task Force Company Limited By Guarantee
INCOME AND EXPENDITURE ACCOUNT
for the financial year ended 31 December 2021

	Notes	2021 €	2020 €
Income		357,301	338,609
Expenditure		(353,601)	(349,434)
Surplus/(deficit) before tax		3,700	(10,825)
Tax on surplus/(deficit)		-	-
Surplus/(deficit) for the financial year		3,700	(10,825)
Total comprehensive income		3,700	(10,825)

Approved by the board on 29 March 2022 and signed on its behalf by:


Joseph O'Neill
Director


Joseph McDonagh
Director

Western Region Drugs Task Force Company Limited By Guarantee


BALANCE SHEET

as at 31 December 2021


	Notes	2021 €	2020 €
Fixed Assets			
Tangible assets	8	10,674	9,629
Current Assets			
Debtors	9	12,689	11,527
Cash and cash equivalents		4,825	49,821
		17,514	61,348
Creditors: amounts falling due within one year	10	(6,355)	(52,844)
Net Current Assets		11,159	8,504
Total Assets less Current Liabilities		21,833	18,133
Reserves			
Income and expenditure account		21,833	18,133
Members' Funds		21,833	18,133

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on 29 March 2022 and signed on its behalf by:



Joseph O'Neill
Director



Joseph McDonagh
Director

Western Region Drugs Task Force Company Limited By Guarantee
RECONCILIATION OF MEMBERS' FUNDS

as at 31 December 2021

	Retained surplus	Total
	€	€
At 1 January 2020	28,958	28,958
Deficit for the financial year	(10,825)	(10,825)
At 31 December 2020	18,133	18,133
Surplus for the financial year	3,700	3,700
At 31 December 2021	<u>21,833</u>	<u>21,833</u>

Western Region Drugs Task Force Company Limited By Guarantee

CASH FLOW STATEMENT

for the financial year ended 31 December 2021

	Notes	2021 €	2020 €
Cash flows from operating activities			
Surplus/(deficit) for the financial year		3,700	(10,825)
Adjustments for:			
Depreciation		2,375	2,705
		<u>6,075</u>	<u>(8,120)</u>
Movements in working capital:			
Movement in debtors		(1,162)	11,907
Movement in creditors		(46,489)	(1,780)
		<u>(41,576)</u>	<u>2,007</u>
Cash flows from investing activities			
Payments to acquire tangible assets		(3,420)	(2,570)
		<u>(44,996)</u>	<u>(563)</u>
Net decrease in cash and cash equivalents		49,821	50,384
Cash and cash equivalents at beginning of financial year		49,821	50,384
Cash and cash equivalents at end of financial year	18	<u>4,825</u>	<u>49,821</u>

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2021

1. General Information

Western Region Drugs Task Force Company Limited By Guarantee is a company limited by guarantee incorporated and registered in the Republic of Ireland. The registered number of the company is 460340. The registered office of the company is Unit 6 Galway Technology Park, Parkmore, Galway. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2021 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income

Grants

Grant Income from government agencies and other sundry sources are included in the Financial Statements on the basis of the amounts received and receivable.

Income

Income consisting of donations and other funds generated by voluntary activity are included in the Financial Statements when received. Income from these sources have been included in the Financial Statements only when realised or when the ultimate cash realisation of which can be assessed with reasonable certainty.

Fund Accounting

The following funds are operated by the charity:

- Restricted Funds

Restricted funds represent grants, donations and sponsorship received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the directors. Such purposes are within the overall aims of the charity.

- Unrestricted Funds

Unrestricted Funds represent amounts which are expendable at the discretion of the directors in furtherance of the objectives of the charity and which have not been designated for other purposes. Such funds may be held in order to finance working capital or capital expenditure.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight Line
----------------------------------	-----------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable income for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income and Expenditure Account.

3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. Going concern

The Financial Statements have been prepared on the going concern basis of accounts preparation, the validity of which depends upon future funding being available on a continuous basis from government agencies. The Directors are taking all necessary steps to ensure the continuation of support from the company's funding agencies. The Directors are confident that the company will receive funding for the foreseeable future which will allow the company to continue to operate. This uncertainty could result in the company being unable to realise its assets and discharge its liabilities in the normal course of business.

5. Provisions Available for Audits of Small Entities

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the Revenue and to assist with the preparation of the financial statements.

6. Operating surplus/(deficit)	2021	2020
	€	€
Operating surplus/(deficit) is stated after charging:		
Depreciation of tangible assets	2,375	2,705

7. Employees

There were no employees in the company during the year.

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

8. Tangible assets

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 January 2021	21,643	21,643
Additions	3,420	3,420
At 31 December 2021	25,063	25,063
Depreciation		
At 1 January 2021	12,014	12,014
Charge for the financial year	2,375	2,375
At 31 December 2021	14,389	14,389
Net book value		
At 31 December 2021	10,674	10,674
At 31 December 2020	9,629	9,629

9. Debtors

	2021 €	2020 €
Taxation	2	2
Prepayments	12,687	11,525
	12,689	11,527

10. Creditors

Amounts falling due within one year	2021 €	2020 €
Accruals	4,305	4,305
Deferred Income	2,050	48,539
	6,355	52,844

Repayment Terms

Accruals do not attract interest and their terms vary depending on contracts in place. Other Creditors do not attract interest and are due for immediate payment. Deferred Income is repayable in the event that funding is not used for the purpose for which it was intended.

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

11. State Funding

Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway and Roscommon
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Planet Youth Model for Primary Prevention
Total Grant	€3,750
Grant taken to I&E	€3,750
Received in the financial year	€3,750
Amounts deferred or due at financial year end	Nil
Expenditure	€3,750 (Payment made on 4/11/2021)
Term	12 Months (January 2021 - December 2021)
Date Received	10/09/2021
Capital Grant	Nil
Restriction on Use	Restricted to implementing the planet youth model for primary prevention of substance use.
Tax Clearance	Yes
Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway
Grant Programme	Planet Youth
Purpose of the Grant	Planet Youth Guidelines booklets 2021-2022
Total Grant	€3,680
Grant taken into I&E	€3,680
Received in the financial year	€3,680
Amounts deferred or due at financial year end	Nil
Expenditure	€3,680 (Payment made on 28/07/2021)
Term	12 Months (January 2021 - December 2021)
Date Received	20/09/2021
Capital Grant	Nil
Restricted on Use	Restricted to the planet youth guidelines booklets
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway & Roscommon
Grant Programme	Community Liaison Worker Roscommon
Purpose of the Grant	To pay for a part time Community Liaison worker in County Roscommon
Total Grant	€25,000
Grant taken into I&E	€25,000
Received in the financial year	€25,000
Amounts deferred or due at financial year end	Nil
Expenditure	€25,000 (Payment of €10,000 on 17/9/2021, €9,000 on 20/09/2021 & €6,000 on 21/09/2021)
Term	12 Months (January 2021 - December 2021)
Date Received	03/09/2021
Capital Grant	Nil
Restricted on Use	Restricted to pay for a part time Community Liaison worker in County Roscommon
Tax Clearance	Yes
Agency	TUSLA - Child and Family Agency
Type of Funding	CYPSC Galway & Roscommon
Grant Programme	Community Liaison worker Roscommon
Purpose of the Grant	Parental Participation Seed Funding
Total Grant	€4,961.48
Grant taken into I&E	€4961.48
Received in the financial year	€4961.48
Amounts deferred or due at financial year end	Nil
Expenditure	€4,961.48 (Payment made on 15/12/2021)
Term	12 Months (January 2021 - December 2021)
Date Received	03/09/2021
Capital Grant	Nil
Restricted on Use	Restricted to parental participation seed funding
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Agency	TUSLA - Child and Family Agency
Type of Funding	CYPSC Roscommon
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Planet Youth model for Primary Prevention including sleep matters
Total Grant	€3,000
Grant taken into I&E	€3,000
Received in the financial year	€3,000
Amounts deferred or due at financial year end	Nil
Expenditure	€3,000 (Payment €1,362 on 17/11/2021, €904 on 29/11/2021, €628 on 03/12/2021 & €106 on 18/11/2021)
Term	12 Months (December 2021 - November 2021)
Date Received	12/11/2021
Capital Grant	Nil
Restriction on Use	Restricted to implementing the planet youth model for primary prevention of substance use
Tax Clearance	Yes
Agency	TUSLA - Child and Family Agency
Type of Funding	Tusla Central
Grant Programme	Covid -19
Purpose of the Grant	To prevent the spread of Covid in the office
Total Grant	€1,250
Grant taken into I&E	€1,250
Received in the financial year	€1,250
Amounts deferred or due at financial year end	€1,250
Expenditure	Nil
Term	12 Months
Date Received	05/11/2021
Capital Grant	Nil
Restriction on Use	Restricted to payment to prevent the spread of Covid in the office
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Agency	HSE
Type of Funding	Department of Health
Grant Programme	Strand 1 Funding
Purpose of Grant	To provide bursaries to individuals in need of Rehabilitation
Total Grant	€10,000 plus €7,555 received in 2020
Grant taken to I&E	€17,555
Received in period	€10,000
Amount deferred or due at financial year end	Nil
Expenditure	€17,555
Term	12 Months (January 2021 - December 2021)
Date Received	12/02/2021, 26/03/2021, 18/06/2021 & 27/09/2021
Capital Grant	Nil
Restriction on use	Restricted to the provision of bursaries to individuals in need of Rehabilitation
Tax Clearance	Yes
Agency	HSE
Type of Funding	Department of Health
Grant Programme	Strand 2 Funding
Purpose of Grant	To pay for a Family Support Worker at Ardaun, Roscam & Doughiska Family Resource Centre
Total Grant	€60,000
Grant taken into I&E	€60,000
Received in the financial year	€60,000
Amounts deferred or due at financial year end	Nil
Expenditure	€60,000
Term	12 Months (1st January 2021 to 31st December 2021)
Date Received	12/02/2021, 26/03/2021, 18/06/2021 & 27/09/2021
Capital Grant	Nil
Restriction on Use	To pay for a Family Support Worker at Ardaun, Roscam & Doughiska Family Resource Centre
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Agency	HSE
Type of Funding	Department of Health
Grant Programme	Covid 19 Support
Purpose of Grant	To assist with the impact & protect against the Covid 19 pandemic
Total Grant	€20,000
Grant taken into I&E	€20,000
Received in the financial year	€20,000
Amounts deferred or due at financial year end	Nil
Expenditure	€20,000
Term	12 Months (January 2021 to December 2021)
Date Received	19/02/2021
Capital Grant	Nil
Restricted on Use	To assist with the impact & protect against the Covid 19 pandemic
Tax Clearance	Yes
Agency	HSE
Type of Funding	Department of Health
Grant Programme	National Lottery
Purpose of Grant	To assist with the Planet Youth project
Total Grant	€2,500
Grant taken into I&E	€2,500
Received in the financial year	€2,500
Amounts deferred or due at financial year end	Nil
Expenditure	€2,500
Term	12 Months (January 2021 - December 2021)
Date Received	06/08/2021
Capital Grant	Nil
Restricted on Use	Restricted to the Planet Youth project
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

Agency	HSE
Type of funding	Department of Health
Grant Programme	Ballinrobe Family Resource Centre
Purpose of the Grant	To pay for a Family Support worker in Ballinrobe
Total Grant	€46,326
Grant taken into I&E	€46,326
Received in the financial year	€46,326
Amounts deferred or due at financial year end	Nil
Expenditure	€46,326
Term	12 Months (January 2021 to December 2021)
Date Received	12/02/2021, 26/03/2021, 18/06/2021 & 27/09/2021
Capital Grant	Nil
Restricted on Use	To pay for a Family Support Worker at Ballinrobe Family Resource Centre
Tax Clearance	Yes

12. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 1.

13. Capital commitments

The company had no material capital commitments at the financial year-ended 31 December 2021.

14. Contingent liabilities

The company is funded by the provision of grant aid from the Health Service Executive (HSE) & TUSLA . These grants may become repayable in the whole or in part if the company does not adhere to terms and conditions set down in funding agreements.

15. Directors' remuneration

No director received any remuneration for their services as director of the company. In addition, no director received any fees, expenses or any other benefit from the company during the year. There were no pension contributions made by the company in respect of any of the company directors.

16. Related party transactions

There were no related party transactions with the directors during the period.

17. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2021

18. Cash and cash equivalents	2021 €	2020 €
Cash and bank balances	3,981	3,654
Cash equivalents	844	46,167
	<u>4,825</u>	<u>49,821</u>

19. Reserves

Reserves represent the accumulated surplus earned by the company since incorporation and are carried forward from unrestricted funds.

20. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 29 March 2022.

WESTERN REGION DRUGS TASK FORCE COMPANY LIMITED BY GUARANTEE

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

NOT COVERED BY THE REPORT OF THE AUDITORS

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

Western Region Drugs Task Force Company Limited By Guarantee
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
TRADING STATEMENT
for the financial year ended 31 December 2021

	Schedule	2021 €	2020 €
Income			
Unrestricted Funding - HSE Funding		91,841	91,841
Restricted Funding - HSE Funding (Family Support Mayo)		46,326	46,326
Restricted Funding - Family Support (ARD Family Resource Centre)		-	30,179
Restricted Funding - HSE National Lottery Grants		2,500	-
Restricted Funding - HSE Funding (Strand 1 Bursaries Income)		17,555	13,601
Restricted Funding - HSE Strand 2 Funding		60,000	100,000
Restricted Funding - Tusla Funding (Planet Youth)		15,392	37,772
Restricted Funding - Forolge		1,500	-
Restricted Funding - Other Sources		1,020	674
Restricted Funding - Rethink Ireland (Planet Youth)		40,000	-
Restricted Funding - Sexual Health West		750	-
Restricted Funding - DCEIDY Funding		4,000	-
Restricted Funding - Tusla (CLW Roscommon)		25,000	-
Restricted Funding - Midlands RDAFT		1,000	-
Restricted Funding - Health & Wellbeing Mayo		3,750	-
Restricted Funding - HSE (Covid Support)		20,000	-
Restricted Funding - HSE (Healthy Cities Funding)		3,750	-
Unrestricted Funding - South West Mayo Development Company		7,984	-
Restricted Funding - Galway City & County Council (Planet Youth)		7,700	7,500
Restricted Funding - Mayo County Council		3,483	3,483
Restricted Funding Health & Wellbeing (Planet Youth)		-	3,483
Restricted Funding - Roscommon County Council/Healthy Ireland Roscommon		3,750	3,750
		<u>357,301</u>	<u>338,609</u>
Gross surplus Percentage		<u>100.0%</u>	<u>100.0%</u>
Overhead expenses	1	(353,601)	(349,434)
Net surplus/(deficit)		<u><u>3,700</u></u>	<u><u>(10,825)</u></u>

Western Region Drugs Task Force Company Limited By Guarantee
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS
SCHEDULE 1 : OVERHEAD EXPENSES
for the financial year ended 31 December 2021

	2021 €	2020 €
Administration Expenses		
WRDATF Training Calendar	11,219	14,942
Putting the Pieces Together	10,500	-
Rent & Services payable	23,901	26,136
Light and heat	4,938	3,788
Cleaning & Waste	1,038	1,358
Repairs and maintenance	296	302
Printing, postage and stationery	6,234	5,217
Telephone & Broadband	5,063	4,421
Computer costs	2,498	1,777
Galway Safe App Development	4,468	-
Digital Technology	2,927	1,627
Learn Upon Platform	7,612	-
Training Ancillary Costs	-	1,758
Accountancy	1,885	1,885
Bank charges	117	118
Rehab Bursary Applications	23,363	13,600
Ballinrobe Family Resource Centre	66,312	52,035
Ardaun Roscam Doughiska FRC	30,000	130,000
Plant Youth	105,437	53,543
Awareness Week	749	1,802
Family Support Development	6,228	-
Roscommon Leader Partnership	25,000	30,000
Hope House	5,091	-
We Works DCYI Fund	4,000	-
Auditor's remuneration	2,350	2,420
Depreciation of tangible assets	2,375	2,705
	353,601	349,434